GlaxoSmithKline, which makes the controversial diabetes drug Avandia, is under deep trouble as medical advisers have voiced their concern about Avandia being a safe drug.

Food and Drug Administration will get the committee's vote, which is suppose to decide the trustworthiness and safety of the drug, on Wednesday.

Glaxo hid important safety data from the public; this is what internal company documents have stated in recent days.

A major clinical trial, nicknamed Record, was not included in the final tally of the study, this has been stated by a federal medical officer after a review of Record. This clinical trial found various heart attack instances.

J. Paul Sizemore, a California lawyer, said, the company on Tuesday settled a lawsuit with plaintiffs who stated that the drug caused strokes and heart attacks. It has been told by him that $460 million was being paid by the company about which there were no comments from it.

Dr. Nancy L. Geller, a committee member who is director of the Office of Biostatistics Research at the National Heart, Lung and Blood Institute, said, "I am concerned about data quality over all."

First day of the meeting was controversial as many experts gave conflicting views on Avandia's safety.

Options regulators can think about various ways to avoid Avandia's negative impact by limiting doctor's prescription about the drug, adding more warning labels, or completely pulling it from the market.